MedTrace Logo

Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia

NCT02956967 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 171

Last updated 2019-02-11

Study results available
· View outcomes & findings →

Summary

Non-interventional, non-comparative, national, multi-site, single-arm prospective observational study to investigate home administration of Nivestim in the primary prophylaxis of chemotherapy-Induced febrile neutropenia

Conditions

  • Non-Interventional Study

Interventions

OTHER

Overall satisfaction questionnaires of home use of Nivestim

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-23
Primary Completion
2016-12-12
Completion
2016-12-12

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02956967 on ClinicalTrials.gov